Evaluation of multiple screening methods for cervical cancers in rural areas of Xinjiang, China

Naizhaer, Gulimire; Yuan, Jianlin; Mijiti, Patima; Aierken, Kailibinuer; Abulizi, Guzhalinuer; Qiao, You‐Lin

doi:10.1097/md.0000000000019135

Cited by 12 publications

(12 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Additionally, HPV mRNA and signal amplification can be detected via liquid-phase or in situ hybridization methods, as applied in Hybrid Capture 2 (HC2) (Qiagen Gaithersburg, MD, USA) [ 85 ]. Other validated commercial HPV tests used across the region include the Cervista HPV HR Test (Hologic, Madison, WI, USA) [ 140 ], careHPV Test (Qiagen Gaithersburg, MD, USA) [ 140 ], Linear Array (Roche Molecular Systems Inc., Pleasanton, CA, USA) [ 49 , 141 , 142 , 143 ], Cobas 4800 HPV Test (Roche Molecular Systems Inc., CA, USA) [ 140 , 144 ], Xpert HPV (Cepheid, CA, USA) [ 145 ], INNO-LiPA HPV Genotyping (Fujirebio, Gent, Belgium) [ 146 , 147 , 148 , 149 ], and Luminex Genotyping GP HR (Diassay, Netherlands) [ 150 ]. Additionally, there are wide varieties of commercial HPV genotyping kits that can simultaneously detect more than 20 HPV genotypes.…”

Section: Hpv Screeningmentioning

confidence: 99%

Current Updates on Cancer-Causing Types of Human Papillomaviruses (HPVs) in East, Southeast, and South Asia

Xia

Long

et al. 2021

Cancers

View full text Add to dashboard Cite

Human papillomavirus (HPV) infection remains one of the most prominent cancer-causing DNA viruses, contributing to approximately 5% of human cancers. While association between HPV and cervical cancers has been well-established, evidence on the attribution of head and neck cancers (HNC) to HPV have been increasing in recent years. Among the cancer-causing HPV genotypes, HPV16 and 18 remain the major contributors to cancers across the globe. Nonetheless, the distribution of HPV genotypes in ethnically, geographically, and socio-economically diverse East, Southeast, and South Asia may differ from other parts of the world. In this review, we garner and provide updated insight into various aspects of HPV reported in recent years (2015–2021) in these regions. We included: (i) the HPV genotypes detected in normal cancers of the uterine cervix and head and neck, as well as the distribution of the HPV genotypes by geography and age groups; (ii) the laboratory diagnostic methods and treatment regimens used within these regions; and (iii) the oncogenic properties of HPV prototypes and their variants contributing to carcinogenesis. More importantly, we also unveil the similarities and discrepancies between these aspects, the areas lacking study, and the challenges faced in HPV studies.

show abstract

Section: Hpv Screeningmentioning

confidence: 99%

Current Updates on Cancer-Causing Types of Human Papillomaviruses (HPVs) in East, Southeast, and South Asia

Xia

Long

et al. 2021

Cancers

View full text Add to dashboard Cite

show abstract

“…However, the specificity and sensitivity of TCT are still relatively low. [4][5][6] Serum carbohydrate antigen 153 (CA153) and carbohydrate antigen 50 (CA50), as tumor markers, can be used for joint detection to improve the accuracy of disease diagnosis. It has been applied in the early diagnosis of diseases such as cervical cancer, endometrial cancer, breast cancer and rheumatoid arthritis.…”

Section: Introductionmentioning

confidence: 99%

Value of TCT combined with serum CA153 and CA50 in early diagnosis of cervical cancer and precancerous lesions

Li¹,

Sun³

et al. 2022

Pak J Med Sci

View full text Add to dashboard Cite

Objectives: To determine the application value of thinprep cytologic test (TCT) combined with serum carbohydrate antigen 153 (CA153) and carbohydrate antigen 50 (CA50) detection in the early diagnosis and screening of cervical cancer and precancerous lesions. Methods: A total of 187 females with cervical lesions admitted to Shanghai 7th People’s Hospital Affiliated to Shanghai University of Traditional Chinese Medicine from January 2017 to December 2018 were selected and divided into two groups: the cervical cancer group and the cervical precancerous lesion group, with 16 cases in the cervical cancer group and 171 cases in the cervical precancerous lesion group (cervical precancerous lesions were divided into 63 cases of the CNI group, 59 cases of the CNII group and 49 cases of the CNIII group). During the same period, 106 healthy females were selected as the healthy group. The serum tumor markers CA153 and CA50 of all subjects were detected by chemiluminescence method; The diagnostic value of TCT combined with serum CA153 and CA50 in cervical cancer and precancerous lesions was analyzed with colposcopy pathological diagnosis results as gold standard; ROC curve was drawn to evaluate the diagnostic value of serum TCT, CA153 and CA50 in cervical cancer and precancerous lesions. Results: The levels of serum CA153 and CA50 in the cervical cancer group were significantly higher than those in the cervical precancerous lesion group and the healthy group (p< 0.05), and the levels of serum CA153 and CA50 in the cervical precancerous lesion group were significantly higher than those in the healthy group (p< 0.05). The sensitivity of TCT, serum CA153 and serum CA50 in the single detection of cervical cancer and precancerous lesions was 95.93%, 97.54% and 96.00%, the specificity was 59.41%, 60.23%, 60.12%, the accuracy was 74.74%, 75.77%, 75.43%, the positive predictive value was 62.03%, 63.64%, 63.10%, and the negative predictive value was 96.22%, 97.17% and 95.28%, respectively. The sensitivity, specificity, accuracy, positive predictive value and negative predictive value of TCT combined with serum CA153 and CA50 were 96.77%, 73.19%, 85.67%, 80.21% and 95.28%, respectively. ROC curve showed that the area under the curve (AUC) of TCT and serum CA153 and CA50 in the single detection of cervical cancer and precancerous lesions was 0.791, 0.864 and 0.787, respectively, the AUC of combined detection of TCT and serum CA153 and CA50 in patients with cervical cancer and precancerous lesions was 0.877, which was significantly higher than that of single detection (p< 0.05). Conclusions: TCT combined with serum CA153 and CA50 has been reported as a treatment regimen with high accuracy, which has a high diagnostic efficiency for early diagnosis of cervical cancer and precancerous lesions, and can significantly improve the sensitivity. doi: https://doi.org/10.12669/pjms.38.6.5503 How to cite this:Li H, Li L, Sun J, Dong S, Li H. Value of TCT combined with serum CA153 and CA50 in early diagnosis of cervical cancer and precancerous lesions. Pak J Med Sci. 2022;38(6):---------. doi: https://doi.org/10.12669/pjms.38.6.5503 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

show abstract

“…Cervical cancer is one of the greatest threats to women’s well-being, which places a tremendous financial burden and mental tension on affected individuals and families and increases national budget consumption for health [ 1 2 ]. Cervical cancer is confirmedly caused by persistent high-risk human papillomavirus (Hr-HPV) infection.…”

Section: Introductionmentioning

confidence: 99%

Possible different genotypes for human papillomavirus vaccination in lower middle-income countries towards cervical cancer elimination in 2030: a cross-sectional study

Utami

Andrijono

Putra

et al. 2022

Clin Exp Vaccine Res

View full text Add to dashboard Cite

Purpose Human papillomavirus (HPV) genotype and age distribution of HPV infection were crucial for the national vaccination and screening program planning. However, there was a limited study providing these data in the normal cervix population. This study aimed to explore the HPV genotypes profile of women with clinically normal cervix based on Visual Inspection of Acetic Acid (VIA) test. Materials and Methods A 7-year cross-sectional study was conducted from 2012 to 2018 in private and public health care centers in Jakarta. Subjects were recruited consecutively. Data were collected by anamnesis, VIA, and HPV DNA test using the polymerase chain reaction (PCR; SPF10-DEIA-LiPA25) method. HPV genotyping procedures include DNA extraction, PCR (SPF10-DEIA-LiPA25) using the HPV XpressMatrix kit (PT KalGen DNA, East Jakarta, Indonesia), and hybridization. The IBM SPSS ver. 20.0 (IBM Corp., Armonk, NY, USA) were used to analyze the data. Results A total of 1,397 subjects were collected. Positive HPV-DNA tests were found in 52 subjects (3.7%); 67% were single and 33% were multiple HPV infections. HPV 52 was the most frequently detected HPV genotype, followed by HPV 39, 16, 18 74, 44, 31, 54, and 66, respectively. The highest HPV infections in this population were in the 31–40 and 41–50 years old group. Conclusion This study suggested beneficial screening for women aged 31–50 years old. Instead of “original” nonavalent (HPV 16, 18, 6, 11, 31, 33, 45, 52, 58), the different “nonavalent” formula for HPV vaccines protecting against HPV 16, 18, 6, 11, 31, 39, 44, 52, 74 might be useful for Indonesian population. However, further multicenter studies with a huge sample size are still needed.

show abstract

Evaluation of multiple screening methods for cervical cancers in rural areas of Xinjiang, China

Cited by 12 publications

References 9 publications

Current Updates on Cancer-Causing Types of Human Papillomaviruses (HPVs) in East, Southeast, and South Asia

Current Updates on Cancer-Causing Types of Human Papillomaviruses (HPVs) in East, Southeast, and South Asia

Value of TCT combined with serum CA153 and CA50 in early diagnosis of cervical cancer and precancerous lesions

Possible different genotypes for human papillomavirus vaccination in lower middle-income countries towards cervical cancer elimination in 2030: a cross-sectional study

Contact Info

Product

Resources

About